

GLAXOSMITHKLINE PLC  
Form 6-K  
October 11, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending October 2011

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline PLC

Blocklisting Application

Application has been made to the Financial Services Authority and the London Stock Exchange Plc for a total of 20,000,000 ordinary shares of 25p each ("shares") to be admitted to the Official List.

These shares are being reserved under block listings and will be issued as a result of the award of shares pursuant to the following schemes:

| Scheme  | Shares     |
|---|------------|
| GlaxoSmithKline Share Option Plan - Ordinary shares | 10,000,000 |
| GlaxoSmithKline Share Option Plan - ADS             | 5,000,000  |
| GlaxoSmithKline Savings Related Share Option Scheme | 5,000,000  |

When issued, these shares will rank pari passu with the existing ordinary shares.

Victoria Whyte  
Company Secretary

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 10, 2011

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc